Literature data on the overuse and misuse of diagnostic procedures leading to end-of-life aggressiveness are scarce due to the limited amount of estimated economic waste. This study investigated the potential overuse of diagnostic procedures in a population of end-of-life patients.

Background: The increasing prevalence of chronic diseases makes identifying patients in need of palliative care essential for public health systems. Several tools have been developed to identify patients with palliative care needs and limited life expectancy. This study aimed to evaluate the performance of the NECPAL and PaP tools in patients with advanced chronic diseases and to explore their potential role in identifying palliative care needs and prognostic assessment. Methods: Prospective, observational, multicenter study using the Necesidades Paliativas tool (NECPAL CCOMS-ICO version 1.0), Palliative Prognostic score (PaP score), and functional and symptom assessment tools (Palliative Performance Scale and Edmonton Symptom Assessment System), assessed monthly or every two months for up to 12 months. Information on healthcare utilization and end-of-life care was also collected. Sensitivity, specificity, positive/negative predictive value and accuracy were calculated. The study included three groups of patients with advanced chronic diseases: cancer, pulmonary diseases, and renal diseases. The study was reported following the STROBE guidelines. Results: One hundred and ninety-three patients were enrolled: 102 with advanced cancer, 50 with chronic respiratory failure, and 41 with chronic renal failure. The median age was 75 years and 63.7% were male. The overall survival rate was 90% at 30 days and 65% at 12 months. At 30 days, sensitivity and specificity were 100% and 88% for the PaP score, and 89% and 39% for NECPAL. At 12 months, sensitivity and specificity were 20% and 89% for the PaP score, and 88% and 41% for NECPAL. Prognostic accuracy was higher for the PaP score at 30 days (91%) and higher for the NECPAL tool at 12 months (81%). Patients with cancer had more frequent hospitalizations in acute units, while the people living with pulmonary disease had more total hospitalization days. Conclusions: The findings suggest that the two instruments may provide complementary information, although the potential benefit of a combined strategy was not directly evaluated in this study.

Background Glioblastoma (GBM) is a poor prognosis malignant grade 4 glioma. After surgical resection, standard therapy consists of concurrent radiotherapy (RT) and temozolomide (TMZ) followed by TMZ alone. The DC vaccination increased the amount of intratumoral-activated cytotoxic T lymphocytes and decreased the number of FoxP3-positive regulatory T cells. Based on these da-ta, we have developed a phase II protocol with the DC vaccine concomitant to standard RT-CT in patients undergoing surgery for GBM. Methods This is a single-arm, monocentric, phase II trial evaluating progression-free survival (PFS) and the safety of a DC vaccination integrated with standard therapy in resected GBM patients. The vaccine administration begins at the end of the RT-CT (Induction Phase) and is subsequently al-ternated with TMZ cycles (Maintenance Phase). The primary endpoints are PFS and safety. Among the secondary endpoints, are the in vitro and in vivo Immune response evaluations. Results By December 2022 , nine patients had been enrolled in the first step. Two patients progressed within three months after leukapheresis and none had experienced DC vaccine-related G3-4 tox-icity. Five patients had a positive DTH test against KLH. By June 2023. The median OS from leu-kapheresis was 23.1 months and 24.7 from surgery. Conclusions This combination therapy is well-tolerated, and we have achieved the two endpoints required for the first step. Therefore, the study will proceed to enroll the remaining 19 patients.

From an epidemiological perspective, polymorphous low-grade neuroepithelial tumor (PLNTY) represents a small proportion of brain tumors encountered in epilepsy surgery series. Their rarity and relatively recent recognition likely contribute to underdiagnosis and poor prognosis. In terms of histopathological features, they are similar to oligodendrogliomas. Molecular analyses can be used to show the fusion between fibroblast growth factor receptor (FGFR3) and transforming acidic coiled coil (TACC) proteins, which most commonly results in progression towards glioblastoma (GBM). We report a case of a 62-year-old man who underwent left frontal craniotomy to remove a frontal mass. Histologically, the glial lesion consisted of elements associated with oligodendroglia-like features. Immunohistochemistry was positive for glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2), and α-thalassemia X-linked mental retardation syndrome (ATRX) nuclear expression, but negative for isocitrate dehydrogenase 1 (IDH1) and BRAF-V600E. Next-generation sequencing showed the FGFR-TACC3 fusion, and taken together, these findings supported the final diagnosis of PLNTY. During follow-up, the patient underwent a second neurosurgery, where histological evaluation indicated a GMB. This article presents clinical and radiological data, morphology, immunohistochemistry, molecular features, and treatment to enhance the clinical and pathological understanding of PLNTY with FGFR3-TACC3 fusion for all professionals involved in medical decisions.